Aldara

Aldara is a topical cream containing 5% imiquimod, used to treat external genital and perianal warts caused by HPV (human papillomavirus). In the UK it's also licensed for two other conditions — actinic keratoses (sun-damaged skin patches) and superficial basal cell carcinomas — but the focus here is on its use for genital warts. Aldara comes as small single-use sachets, each holding enough cream for one application, and it's applied at home over a course of up to 16 weeks. Like Warticon, it's used on the outside of the skin only — not inside the vagina, on the cervix, inside the urethra, or inside the rectum.

This is the most useful thing to understand about Aldara, because once you grasp how it works, almost every other question — the slow onset, the side effects, the lower recurrence rate — starts to make sense. Aldara doesn't kill wart cells directly. Instead, it activates the local immune system and lets the body do the work itself. Specifically, imiquimod attaches to a receptor called Toll-like receptor 7 (TLR7) on certain immune cells in the skin, and triggers them to release a cocktail of immune signalling molecules — interferon-alpha, tumour necrosis factor, and a handful of others. These signals act like a fire alarm, recruiting and activating the immune cells that recognise and clear HPV-infected tissue. A useful comparison: Warticon is like sending in a chemical demolition team that breaks down wart cells directly. Aldara is like ringing a doorbell on the immune system and asking it to come and deal with the problem itself. The effect is slower, but the immune response that develops also tends to leave a kind of "memory" that helps prevent the warts coming back.

Both medicines treat the same condition but go about it in genuinely different ways, and the trade-offs matter. Warticon (podophyllotoxin) is a cytotoxic — it kills wart cells directly by stopping them from dividing. Aldara (imiquimod) is an immunomodulator — it stimulates the immune system to clear the infection. Warticon is faster, used in twice-daily three-day cycles over up to four weeks. Aldara is slower, applied three nights a week for up to sixteen weeks. Warticon clears warts more quickly but recurrence rates are higher, because the underlying virus in the surrounding skin isn't directly tackled. Aldara takes longer to work but recurrence rates are lower, because the immune response also helps deal with residual virus in the surrounding skin. Warticon is precisely targeted; Aldara is smeared more broadly across affected areas, which makes it well-suited to scattered warts. Different patients suit different medicines, and a thoughtful prescriber will weigh up wart pattern, lifestyle, previous treatment history, and personal preference rather than picking one by default.

Aldara is applied three nights a week — typically Monday, Wednesday, and Friday, or any pattern with at least one rest night in between — at bedtime. Wash your hands, gently wash and dry the wart area, then squeeze a small amount from the sachet onto a fingertip and rub it gently into the wart and the immediately surrounding skin until it disappears. Wash your hands again. Leave the cream in place overnight, ideally for six to ten hours, then wash it off in the morning with mild soap and water. Don't cover the area with an airtight dressing — the skin needs to breathe. Each sachet is single-use only and should be discarded after each application; the cream isn't meant to be saved for a second go. Most boxes contain twelve sachets, which covers four weeks at three applications per week.

Up to 16 weeks. This often surprises patients who are used to thinking of medicines as working in days or weeks, not months — but the slower timescale is a feature of the mechanism, not a bug. The immune system needs time to build up its response, recognise the infected tissue, and clear it. Many people see their warts begin to shrink within four to eight weeks, and full clearance — where it's going to happen — typically occurs by twelve to sixteen weeks. If warts have completely cleared earlier, you can stop. If there's been no response at all by around eight weeks, it's worth a clinical review rather than continuing blindly.

Aldara is genuinely slower than Warticon, and managing expectations is part of getting through the course. Some people notice changes in the first few weeks — warts becoming inflamed, smaller, or starting to flake — while others see very little until much later in treatment. Local redness or soreness during the first few weeks doesn't mean treatment isn't working; in fact, mild-to-moderate skin reactions are often the first sign that the immune system is responding. Stopping at the first sign of irritation is one of the most common reasons Aldara fails — sticking with it through that early reaction phase is usually the right move, although significant pain or extensive ulceration warrants advice.

Local skin reactions are expected and, within limits, even welcome. The most commonly reported are redness, scabbing, flaking, itching, burning, tenderness, and shallow erosions at the treated site. These usually peak in the middle of the course and settle as warts clear. More severe reactions — large painful ulcers, extensive bleeding, or significant swelling — mean you should pause treatment and seek advice, because the cream may need to be stopped, reduced in frequency, or changed. Some people develop hypopigmentation — a temporary or sometimes longer-lasting lightening of the skin in treated areas — which is worth being aware of, particularly for people with darker skin tones, although it doesn't reflect any underlying damage. Allergic contact dermatitis is occasionally reported.

Because Aldara works by activating the immune system, some of the immune signalling molecules it triggers — interferons in particular — are the same ones the body releases during viral infections, and they can produce flu-like symptoms: tiredness, mild fever, headache, muscle aches, and a generally washed-out feeling. These tend to be mildest in the first few applications, more noticeable in the middle of the course, and they usually settle within a day or two of each application. They aren't a sign of an allergic reaction or of treatment failure — they're a sign the cream is doing what it's designed to do. If symptoms are severe or persistent, particularly with high fever or significant breathlessness, that's a different picture and warrants medical advice.

Within reason, yes — and this is one of the most useful pieces of context to hold on to during treatment. A moderate local skin reaction (redness, mild soreness, some flaking) is often a marker that the immune response is engaged and the cream is working. Studies have shown that people who experience these reactions tend to have higher clearance rates than those who don't. That said, "more reaction equals more effect" only holds up to a point. Severe reactions — extensive ulceration, marked swelling, intolerable pain, signs of secondary infection — are not desirable and need to be acted on. The judgement call isn't always easy, which is why dose adjustment (for example, dropping from three nights a week to two for a few weeks) is a normal part of how Aldara is used in practice. If you're unsure where on that spectrum your reaction sits, send a photo or visit a clinician rather than guessing.

Yes — and this is a critical safety point that's easy to miss. Aldara cream contains ingredients that can weaken latex condoms and diaphragms, which means barrier contraception cannot be reliably used on nights when the cream is on the skin. The implications matter on two fronts: contraception (a weakened condom can split) and STI protection (a weakened condom won't protect either partner). If pregnancy or STI prevention is relevant to you, the simplest approach is to avoid sex on application nights altogether and resume only after the cream has been washed off in the morning and any active soreness has settled. If sex during the treatment period is unavoidable and a barrier method matters, polyurethane or polyisoprene non-latex condoms aren't affected in the same way and can be a reasonable alternative — but this is worth flagging with your prescriber so a contraceptive plan is in place before you start.

Sex with the cream on the skin should be avoided — it transfers to a partner, gets washed off the wart, and can irritate already-inflamed tissue. After the cream has been washed off in the morning, sex isn't medically contraindicated, although many people find treated skin too sore to be comfortable, particularly during the middle weeks of the course. Beyond the practical comfort issue, it's worth remembering that visible warts indicate active HPV, so partners may be exposed if barriers aren't used — and as already noted, latex barriers are unreliable on application nights. Many couples find that a treatment break from penetrative sex for the duration of the course is the simplest plan, with a return to normal once the warts have cleared and the skin has fully healed.

Aldara is generally avoided in pregnancy unless the benefit clearly outweighs the risks, and the call should be made with a clinician rather than independently. The good news is that imiquimod doesn't carry the same firm contraindication as podophyllotoxin — there's no clear evidence of teratogenicity — but the safety data in pregnancy is limited, and most guidance errs on the side of caution. If you're pregnant or trying to conceive, alternative treatments such as cryotherapy or trichloroacetic acid in clinic are usually preferred, and many small genital warts in pregnancy are simply observed, because they often clear or shrink after delivery as the immune system rebalances. Aldara should also be avoided while breastfeeding, partly because of limited safety data and partly because of the theoretical possibility of cream transfer if warts are in an area that could come into contact with the baby.

Recurrence is genuinely less common with Aldara than with Warticon — typically reported in around 10 to 20 per cent of patients after Aldara, compared with 30 to 40 per cent or more after podophyllotoxin in some studies. The likely reason is exactly the mechanism we covered earlier: because the immune system has been trained to recognise and respond to HPV-infected tissue, it tends to keep on doing so for a period after treatment ends, dealing with residual virus in surrounding skin before new warts can form. This isn't a guarantee — recurrences do happen, and they can be treated with another course of Aldara, with Warticon, or with a clinic-based approach — but the lower recurrence rate is one of the main reasons many prescribers favour Aldara despite its slower onset.

If there's been no response at all by eight weeks of treatment, or if warts persist after the full sixteen weeks, a different approach is usually needed. Options include switching to Warticon (a cytotoxic mechanism may succeed where an immune-mediated one didn't, and vice versa), cryotherapy in clinic, trichloroacetic acid, or minor surgical or electrosurgical removal — particularly useful for larger or resistant warts. Sometimes a combination approach works best: Warticon to reduce wart bulk, then Aldara to reduce the chance of recurrence, or surgical removal followed by Aldara to clear residual disease. A sexual health clinic or specialist dermatology service can choose the next step based on the wart pattern, your treatment history, and any underlying factors such as immune suppression that might be making warts harder to clear.

This is increasingly being recognised as a sensible approach for some patients — though it should always be guided by a prescriber rather than improvised at home. A common pattern is to use Warticon first to rapidly reduce the bulk of visible warts, then move to Aldara to mop up residual disease and reduce the chance of recurrence. The two medicines have different mechanisms and different application schedules, which means combining them sequentially is usually feasible. Using them simultaneously on the same skin isn't recommended, because the combined irritation can become significant and unpredictable. If your prescriber has suggested a sequential approach, follow the plan as set out — and if you're considering combining treatments yourself, please don't, and have the conversation with a clinician instead.

A few situations call for in-person review rather than self-treatment. Any wart that is unusually large, bleeding, painful, pigmented, ulcerated, or rapidly changing in appearance needs assessment, because in rare cases what looks like a wart can be something else. Warts inside the vagina, on the cervix, inside the urethra, or inside the rectum need clinic-based treatments — Aldara is licensed only for external skin. Pregnancy, planning pregnancy, or breastfeeding all warrant a different conversation. Severe local reactions, signs of secondary infection (significant pus, expanding redness, fever), no response at all by eight weeks of treatment, recurrent warts despite multiple courses, immune suppression (for example by HIV or immunosuppressant medications), and any concern about other sexually transmitted infections all justify a sexual health clinic visit. NHS sexual health services are free, confidential, and used to seeing exactly the kind of questions covered above without judgement — there's no need to push through quietly when a brief in-person review can change the plan and make the whole experience easier.